Kiora Pharmaceuticals (KPRX) Share-based Compensation (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Share-based Compensation came in at $1012.0 in Q1 2026, down 99.12% YoY from $114616.0 in Q1 2025, and down 17.52% on a QoQ basis from $1227.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Share-based Compensation (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Share-based Compensation data on file, last reported at $1012.0 in Q1 2026.
- Quarterly Share-based Compensation fell 99.12% year-over-year to $1012.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $222903.0 (down 71.1% YoY) and the FY2025 annual result came in at $336507.0, down 48.75% from the prior year.
- Share-based Compensation fell to $1012.0 in Q1 2026, from $1227.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $656593.0 in Q4 2024 to a low of -$325238.0 in Q3 2024.
- A 5-year average of $204625.8 and a median of $199132.5 in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 260.08% in 2024, down 222.79% in 2024.
- Tracing KPRX's Share-based Compensation over 5 years: stood at $407035.0 in 2022, then sank by 55.2% to $182344.0 in 2023, then surged by 260.08% to $656593.0 in 2024, then sank by 99.81% to $1227.0 in 2025, then retreated by 17.52% to $1012.0 in 2026.
- The last three Share-based Compensation figures came in at $1012.0 (Q1 2026), $1227.0 (Q4 2025), and $1603.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Kiora Pharmaceuticals | 16.19 Mn | 16.19 Mn | - | 109,310.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109,310.00 |
| Jun 30, 2026 | 109,310.00 |
| Mar 31, 2026 | 1,012.00 |
| Mar 31, 2026 | 1,012.00 |
| Dec 31, 2025 | 1,227.00 |
| Dec 31, 2025 | 1,227.00 |
| Sep 30, 2025 | 1,603.00 |
| Sep 30, 2025 | 1,603.00 |
| Jun 30, 2025 | 219,061.00 |
| Jun 30, 2025 | 219,061.00 |
| Mar 31, 2025 | 114,616.00 |
| Mar 31, 2025 | 114,616.00 |
| Dec 31, 2024 | 656,593.00 |
| Dec 31, 2024 | 656,593.00 |
| Sep 30, 2024 | -325,238.00 |
| Sep 30, 2024 | -325,238.00 |
| Jun 30, 2024 | 325,238.00 |
| Jun 30, 2024 | 325,238.00 |
| Dec 31, 2023 | 182,344.00 |
| Dec 31, 2023 | 182,344.00 |